Micromet drug sees leukemia remission in Phase II trial

06/12/2011 | Bloomberg

Interim results of a midstage study indicate that blinatumomab, an investigational drug from Micromet, produced complete remission in nine of 12 patients whose acute lymphoblastic leukemia had relapsed after conventional treatment. The positive data could bring accelerated FDA approval, an analyst said.

View Full Article in:

Bloomberg

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Executive Officer
CarePoint Health Plan
Jersey City, NJ
Regional Director, Southeastern Region - State Affairs
America's Heatlh Insurance Plans (AHIP)
Washington, DC
Assistant General Counsel
Cardinal Health
Columbus, OH
Pharmacy Care Manager
National Association of Chain Drug Stores
Arlington, VA
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC